Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines

Biochemical Pharmacology

Volumn 73, Issue 11, 2007, Pages 1715-1726

  Rakitina, Tatiana V ^a   Vasilevskaya, Irina A ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

17 AAG; Cdk modulators; Cell cycle; Cell death; Oxaliplatin; p21

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; OXALIPLATIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL POPULATION; COLON CANCER; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SENSITIZATION;

CELL CYCLE; CELL DEATH; COLONIC NEOPLASMS; DRUG SYNERGISM; G1 PHASE; GROWTH INHIBITORS; HUMANS; ORGANOPLATINUM COMPOUNDS; S PHASE; TUMOR CELLS, CULTURED;

EID: 34247152620     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.01.037     Document Type: Article

References (41)

1. Johnson S.W., Stevenson P.J., and O'Dwyer P.J. Cisplatin and its analogues. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th ed. (2001), Lippincott Williams & Wilkins, Philadelphia, USA 377-388
2. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
3. el-Akawi Z., Abu-hadid M., Perez R., Glavy J., Zdanowicz J., Creaven P.J., et al. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105 (1996) 5-14
4. Mishima M., Samimi G., Kondo A., Lin X., and Howell S.B. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38 (2002) 1405-1412
5. Boyer J., McLean E.G., Aroori S., Wilson P., McCulla A., Carey P.D., et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10 (2004) 2158-2167
6. Hector S., Bolanowska-Higdon W., Zdanowicz J., Hitt S., and Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48 (2001) 398-406
7. Arnould S., Hennebelle I., Canal P., Bugat R., and Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39 (2003) 112-119
8. Gourdier I., Crabbe L., Andreau K., Pau B., and Kroemer G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23 (2004) 7449-7457
9. Arango D., Wilson A.J., Shi Q., Corner G.A., Aranes M.J., Nicholas C., et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91 (2004) 1931-1946
10. Hayward R.L., Macpherson J.S., Cummings J., Monia B.P., Smyth J.F., and Jodrell D.I. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3 (2004) 169-178
11. Marchetti P., Galla D.A., Russo F.P., Ricevuto E., Flati V., Porzio G., et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 24 (2004) 219-226
12. Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8 (2002) 962-966
13. Rakitina T., Vasilevskaya I., and O'Dwyer P. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res 63 (2003) 8600-8605
14. Arnould S., Guichard S., Hennebelle I., Cassar G., Bugat R., and Canal P. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 64 (2002) 1215-1226
15. Coleman M.L., Marshall C.J., and Olson M.F. Ras promotes p21 (Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 22 (2003) 2036-2046
16. Vasilevskaya I.A., Rakitina T.V., and O'Dwyer P.J. Geldanamycin and its 17-allylamino-17-demethoxy analogue (17-AAG) antagonize the action of cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 63 (2003) 3241-3246
17. Tsai C.M., Gazdar A.F., Venzon D.J., Steinberg S.M., Dedrick R.L., Mulshine J.L., et al. Lack of in Vitro synergy between etoposide and cis-diamminedichloroplatinum (II). Cancer Res 49 (1989) 2390-2397
18. Vasilevskaya I.A., and O'Dwyer P.J. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res 59 (1999) 3935-3940
19. Shapiro G.I., and Harper J.W. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104 (1999) 1645-1653
20. Srethapakdi M., Liu F., Tavorath R., and Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 60 (2000) 3940-3946
21. Munster P.N., Basso A., Solit D., Norton L., and Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 7 (2001) 2228-2236
22. Shaulian E., and Karin M. AP-1 in cell proliferation and survival. Oncogene 20 (2001) 2390-2400
23. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
24. Arlander S.J., Eapen A.K., Vroman B.T., McDonald R.J., Toft D.O., and Karnitz L.M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278 (2003) 52572-52577
25. HTPetak I., Tillman D.M., Harwood F.G., Mihalik R., and Houghton J.A. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res 60 (2000) 2643-2650
26. Lewis J., Devin A., and Miller A. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 275 (2000) 10519-10526
27. Kralj M., Husnjak K., Korbler T., and Pavelic J. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression. Cancer Gene Ther 10 (2003) 457-467
28. Eguchi Y., Shimizu S., and Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57 (1997) 1835-1840
29. Vasilevskaya I.A., Rakitina T.V., and O'Dwyer P.J. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 65 (2004) 235-243
30. Faivre S., Chan D., Salinas R., Woynarowska B., and Woynarowski J.M. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66 (2002) 225-237
31. Park J.W., Yeh M.W., Wong M.G., Lobo M., Hyun W.C., Duh Q.Y., et al. The heat-shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 88 (2003) 3346-3353
32. Braga-Basaria M., Hardy E., Gottfried R., Burman K.D., Saji M., and Ringel M.D. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Clin Endocrinol Metab 89 (2004) 2982-2988
33. Nimmanapalli R., O'Bryan E., Kuhn D., Yamaguchi H., Wang H.-G., and Bhalla K.N. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated down-regulation of AKT. Raf-1 and Src kinases. Neoplasia 102 (2003) 269-275
34. Münster P.N., Marchion D.C., Basso A., and Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 62 (2002) 3132-3137
35. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
36. Sergent C., Franco N., Chapusot C., Lizard-Nacol S., Isambert N., Correia M., et al. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmacol 49 (2002) 445-452
37. Glasgow S.C., Yu J., Carvalho L.P., Shannon W.D., Fleshman J.W., and McLeod H.L. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 92 (2005) 259-264
38. Hata T., Yamamoto H., Ngan C.Y., Koi M., Takagi A., Damdisuren B., et al. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 4 (2005) 1585-1594
39. Vekris A., Meynard D., Haaz M.C., Bayssas M., Bonnet J., and Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64 (2004) 356-362
40. Eastman A., Kohn E.A., Brown M.K., Rathman J., Livingstone M., Blank D.H., et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 1 (2002) 1067-1078
41. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2 (2003) S84-S95